ERBB2 and cancer: In the present study, we studied, for the first time, effector cell pro-inflammatory mechanisms triggered by anti-HER2 IgEs and investigated how these effects are directed against HER2-expressing cancer cells, including those resistant to Tras Fab-mediated effects.